Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YZC | ISIN: CA1079302081 | Ticker-Symbol: 8BT0
Tradegate
24.06.25 | 10:23
2,574 Euro
-1,91 % -0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BRIACELL THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
BRIACELL THERAPEUTICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
2,4822,60111:19

Aktuelle News zur BRIACELL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBriacell Therapeutics Corp (3): Briacell's breast cancer trial gets another DSMB nod5
DiBriaCell Says Independent DSMB Raised No Safety Concerns Of Phase 3 Study Of Bria-IMT Plus CPI3
DiBriaCell setzt Phase-3-Studie zu Brustkrebs nach positiver Sicherheitsüberprüfung fort2
DiBriaCell's phase 3 breast cancer study continues after safety review3
DiBriaCell Therapeutics Corp.: BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer112Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune check point inhibitor Review marks third consecutive positive...
► Artikel lesen
18.06.BriaCell Therapeutics Corp. - 8-K, Current Report4
16.06.BriaCell Therapeutics Corp. - 10-Q, Quarterly Report6
04.06.BriaCell Therapeutics Corp.: BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 267
BRIACELL THERAPEUTICS Aktie jetzt für 0€ handeln
02.06.Stocks in Play: BriaCell Therapeutics Corp.8
02.06.BriaCell Therapeutics Corp.: BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 20253
27.05.Briacell Therapeutics Corp (3): Briacell Bria-OTS clears safety eval in phase 1/2 study21
27.05.Stocks in Play: BriaCell Therapeutics Corp4
27.05.BriaCell erzielt Fortschritte bei Krebsbehandlung mit Bria-OTS in klinischer Studie7
27.05.BriaCell advances cancer treatment with Bria-OTS in clinical study1
27.05.BriaCell Therapeutics Corp.: BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor205Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic...
► Artikel lesen
23.05.BriaCell Therapeutics Corp.: BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 202516
20.05.BriaCell Therapeutics Corp.: BriaCell CEO Letter to Shareholders185Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical candidate Bria-IMT in combination with checkpoint inhibitorBria-IMT has received...
► Artikel lesen
30.04.BriaCell Therapeutics Corp.: BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified261Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 studyBiomarkers could be utilized to predict and provide better patient outcomes, including...
► Artikel lesen
29.04.Briacell Therapeutics Corp (3): Briacell closes $13.8-million public offering11
28.04.BriaCell Therapeutics closes $13.8M public offering2
Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2